conference call

While clearly frustrated by the delay, the CEO doesn't seem too concerned. Says the meeting was positive on both sides and that they got a good hearing.

Bound by confidentiality with the EMA, but said the issues revolve around how the drug would be used. Company have 4 weeks to answer the questions (which they are confident they can do) and then the EMA have to make a decision within 30 days.

One month after approval they can launch the product and bronchitol is already eligible for the health benefit scheme in Germany and the UK.

Have plenty of cash still ( approx 67 million) so no qestion of any cap raising.)

https://services.choruscall.com/links/pharmaxis110127.html#